ABBISKO Aktie

>ABBISKO Performance

1 Woche: +9,8%

1 Monat: +18,7%

3 Monate: +6,6%

6 Monate: -23,6%

1 Jahr: +63,1%

laufendes Jahr: +6,6%

>ABBISKO Aktie

Name:

ABBISKO CAYMAN DL-,00001

Land:

China

Sektor:

Gesundheit

ISIN/ Wkn:

KYG0028A1085 / A3C4Y0

Symbol/ Ticker:

8ZD (Frankfurt)

Kürzel:

FRA:8ZD, ETR:8ZD, 8ZD:GR

Index:

Webseite:

https://www.abbisko.com/

Profil:

Abisko Cayman Ltd. is a company engaged in the provision of specialized financial services. While the exact nature of its services can vary, entities like Abisko Cayman Ltd. typically focus on areas such as asset management, investment advisory, and ..
>Volltext..

Marktkapitalisierung:

991.99 Mio. EUR

Unternehmenswert:

773.3 Mio. EUR

Umsatz:

73.17 Mio. EUR

EBITDA:

Nettogewinn:

5.98 Mio. EUR

Gewinn je Aktie:

0.01 EUR

Schulden:

37.62 Mio. EUR

Liquide Mittel:

92.84 Mio. EUR

Operativer Cashflow:

Bargeldquote:

4.92

Umsatzwachstum:

5.93%

Gewinnwachstum:

55.18%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

ABBISKO, ABBISKO-B

Letzte Datenerhebung:

05.04.26

>ABBISKO Kennzahlen

Aktien/ Unternehmen:

Aktien: 672.7 Mio. St.

Frei handelbar: 65.62%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: 220

Umsatz/Mitarb.: 0.34 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 83.15%

Bewertung:

KGV: 182.11

KGV lG: -

KUV: -

KBV: -

PEG-Ratio: 6.75

EV/EBITDA: -

Rentabilität:

Bruttomarge: 100%

Gewinnmarge: 8.17%

Operative Marge: 3.55%

Managementeffizenz:

Gesamtkaprendite: 2.21%

Eigenkaprendite: 2.54%

>ABBISKO Peer Group

Gesundheit

>ABBISKO Chart & Kurs - Stuttgart

>ABBISKO News

01.04.26 - 04:06	Abbisko Therapeutics′ FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma (PR Newswire)
	SHANGHAI, March 31, 2026 /PRNewswire/ -- 31 March 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that its independently developed, highly selective, oral small-molecule FGFR4 inhibitor irpagratinib (ABSK-011), has been granted Orphan......

31.03.26 - 08:18	Abbisko Therapeutics′ FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children (PR Newswire)
	SHANGHAI, March 31, 2026 /PRNewswire/ -- On 30 March, 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for ABSK061, a highly......

13.01.26 - 02:48	Abbisko Therapeutics Announces FDA Acceptance Of Pimicotinib NDA For Tenosynovial Giant Cell Tumor (AFX)
	HONG KONG (dpa-AFX) - Abbisko Therapeutics Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has formally accepted the New Drug Application (NDA) for pimicotinib (ABSK021). Pimi......

13.01.26 - 01:57	Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor (PR Newswire)
	SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced today that the New Drug Application (NDA) for its novel, orally administered, highly selective, and potent......

22.12.25 - 12:36	Abbisko Therapeutics′ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor (GlobeNewswire EN)
	Based on the positive global Phase III MANEUVER study, the NMPA has granted the world's first regulatory approval for pimicotinib....

16.06.25 - 04:39	Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC (PR Newswire)
	SHANGHAI, June 15, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study of irpagratinib, a self-developed and highly-selective small molecule FGFR4 inhibitor, for the treatment of Hepatocellular......

10.06.25 - 06:06	Abbisko Therapeutics Announces China NMPA Acceptance of New Drug Application for Pimicotinib for the Treatment of TGCT (PR Newswire)
	SHANGHAI, June 10, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for pimicotinib, a highly selective, small-molecule CSF-1R inhibitor, as a Class 1......

26.05.25 - 06:16	Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC (PR Newswire)
	SHANGHAI, May 26, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of......

13.05.25 - 05:36	Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congress (PR Newswire)
	SHANGHAI, May 12, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that updated results from the phase 2 study of irpagratinib (ABSK011) in combination with atezolizumab for the treatment of advanced hepatocellular carcinoma (HCC) will be presented at the......

28.04.25 - 04:03	2025 AACR \| Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1 (PR Newswire)
	SHANGHAI, April 27, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics 02256.HK) today announced that it has presented four late-breaking pre-clinical research posters at the 2025 AACR conference held in Chicago, Illinois (USA) from April 25 to April 30. Results......

01.04.25 - 05:24	Abbisko Says Merck Exercised Option For Global Rights Of Pimicotinib (AFX)
	KENILWORTH (NJ) (dpa-AFX) - Abbisko Therapeutics Co., Ltd. announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee of US$85.0 ......

01.04.25 - 02:51	Merck Exercised the Option for the Global Rights of Abbisko Therapeutics′s Pimicotinib (PR Newswire)
	SHANGHAI, March 31, 2025 /PRNewswire/ -- On April 1, 2025, Beijing Time, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee of USD85.0 million, under the......

28.03.25 - 06:33	Merck übt Option für weltweite Vermarktungsrechte für Pimicotinib aus (Dow Jones)
	DOW JONES--Der Pharma- und Technologiekonzern Merck hat eine Option zur Vermarktung des Wirkstoffkandidaten Pimicotinib von Abbisko Therapeutics in den USA und im Rest der Welt ausgeübt. ......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das sind halt die Freuden eines Preisministers, wenn ab und zu nicht alles teurer wird. - Dr. Josef Staribacher

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram